Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.84% |
| 2 | Technology | 15.57% |
| 3 | Consumer Discretionary | 11.88% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VBIV
3276
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $268K | ﹤0.01% |
22,881
-7,652
| -25% | -$135K |
|
3277
Adicet Bio
ACET
$76.7M
| $266K | ﹤0.01% |
+1,856
| New | +$463K |
|
3278
Milestone Pharmaceuticals
MIST
$132M
| $266K | ﹤0.01% |
+67,200
| New | +$354K |
|
|
OPI
3279
DELISTED
Office Properties Income Trust
OPI
| $266K | ﹤0.01% |
+19,955
| New | +$287K |
|
3280
Arq
ARQ
$101M
| $266K | ﹤0.01% |
109,545
+55,500
| +103% | +$151K |
|
3281
COPT Defense Properties
CDP
$4.22B
| $265K | ﹤0.01% |
+10,200
| New | +$262K |
|
3282
Nektar Therapeutics
NKTR
$2.49B
| $265K | ﹤0.01% |
+7,807
| New | +$378K |
|
|
RPT
3283
Rithm Property Trust
RPT
$104M
| $265K | ﹤0.01% |
6,083
+100
| +2% | +$4.67K |
|
3284
Planet Labs
PL
$8.75B
| $264K | ﹤0.01% |
60,800
-231,300
| -79% | -$1.2M |
|
3285
Healthpeak Properties
DOC
$14.3B
| $263K | ﹤0.01% |
+10,500
| New | +$255K |
|
3286
State Street SPDR EURO STOXX 50 ETF
FEZ
$4.56B
| $263K | ﹤0.01% |
6,794
-1,706
| -20% | -$62.3K |
|
3287
The Greenbrier Companies
GBX
$1.42B
| $262K | ﹤0.01% |
+7,800
| New | +$260K |
|
3288
FlexShares STOXX Global Broad Infrastructure Index Fund
NFRA
$3.05B
| $262K | ﹤0.01% |
+5,200
| New | +$256K |
|
|
RDGT
3289
Ridgetech Inc
RDGT
$3.03M
| $262K | ﹤0.01% |
24
-2
| -8% | -$14.1K |
|
|
CVT
3290
DELISTED
Cvent Holding Corp. Common Stock
CVT
| $262K | ﹤0.01% |
48,600
+8,800
| +22% | +$48.8K |
|
3291
Compass Therapeutics
CMPX
$402M
| $261K | ﹤0.01% |
51,900
-12,315
| -19% | -$49.1K |
|
3292
Magnachip Semiconductor
MX
$137M
| $261K | ﹤0.01% |
+27,843
| New | +$269K |
|
|
YMAB
3293
DELISTED
Y-mAbs Therapeutics
YMAB
| $261K | ﹤0.01% |
53,500
-74,400
| -58% | -$541K |
|
|
LONA
3294
LeonaBio Inc
LONA
$76.3M
| $260K | ﹤0.01% |
8,210
-15,290
| -65% | -$482K |
|
|
CTO
3295
CTO Realty Growth
CTO
$824M
| $260K | ﹤0.01% |
14,201
-79,500
| -85% | -$1.53M |
|
3296
Talkspace
TALK
$871M
| $260K | ﹤0.01% |
426,010
-74,590
| -15% | -$57.4K |
|
3297
GeoVax Labs
GOVX
$3.64M
| $259K | ﹤0.01% |
1,095
-1,693
| -61% | -$514K |
|
|
NAAS
3298
NaaS Technology Inc
NAAS
$57.1M
| $259K | ﹤0.01% |
208
-48
| -19% | -$69.8K |
|
3299
Equinox Gold
EQX
$13.5B
| $258K | ﹤0.01% |
78,600
-91,200
| -54% | -$315K |
|
3300
Disc Medicine
IRON
$3B
| $258K | ﹤0.01% |
12,970
+6,975
| +116% | +$347K |
|
Similar funds
Jim Simons's Q4 2022 Portfolio in Review
As of Q4 2022, Jim Simons held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 524 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Jim Simons added most to Apple in Q4 2022, an estimated $839M increase.
- Jim Simons's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Jim Simons fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Jim Simons's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Jim Simons opened 626 new positions and closed 524 in Q4 2022.
- Jim Simons's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.